These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1448313)

  • 1. Diphtheria-tetanus toxoids-pertussis vaccination does not increase the risk of hospitalization with an infectious illness.
    Joffe LS; Glode MP; Gutierrez MK; Wiesenthal A; Luckey DW; Harken L
    Pediatr Infect Dis J; 1992 Sep; 11(9):730-5. PubMed ID: 1448313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a two-component acellular pertussis vaccine in infants.
    Liese JG; Meschievitz CK; Harzer E; Froeschle J; Hosbach P; Hoppe JE; Porter F; Stojanov S; Niinivaara K; Walker AM; Belohradsky BH
    Pediatr Infect Dis J; 1997 Nov; 16(11):1038-44. PubMed ID: 9384336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
    Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
    Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children.
    Pichichero ME; Badgett JT; Rodgers GC; McLinn S; Trevino-Scatterday B; Nelson JD
    Pediatr Infect Dis J; 1987 Apr; 6(4):352-63. PubMed ID: 3495775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP).
    MMWR Recomm Rep; 1991 Aug; 40(RR-10):1-28. PubMed ID: 1865873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Liang JL; Tiwari T; Moro P; Messonnier NE; Reingold A; Sawyer M; Clark TA
    MMWR Recomm Rep; 2018 Apr; 67(2):1-44. PubMed ID: 29702631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are parental vaccine safety concerns associated with receipt of measles-mumps-rubella, diphtheria and tetanus toxoids with acellular pertussis, or hepatitis B vaccines by children?
    Bardenheier B; Yusuf H; Schwartz B; Gust D; Barker L; Rodewald L
    Arch Pediatr Adolesc Med; 2004 Jun; 158(6):569-75. PubMed ID: 15184221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.
    Glanz JM; Narwaney KJ; Newcomer SR; Daley MF; Hambidge SJ; Rowhani-Rahbar A; Lee GM; Nelson JC; Naleway AL; Nordin JD; Lugg MM; Weintraub ES
    JAMA Pediatr; 2013 Nov; 167(11):1060-4. PubMed ID: 24019039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
    Trollfors B; Knutsson N; Taranger J; Mark A; Bergfors E; Sundh V; Lagergård T
    Eur J Pediatr; 2006 Jan; 165(1):14-8. PubMed ID: 16249929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B.
    Sun Y; Christensen J; Hviid A; Li J; Vedsted P; Olsen J; Vestergaard M
    JAMA; 2012 Feb; 307(8):823-31. PubMed ID: 22357833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
    Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Bryla DA; Robbins JB
    J Pediatr; 1997 Apr; 130(4):532-6. PubMed ID: 9108848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants.
    Lee J; Robinson JL; Spady DW
    BMC Pediatr; 2006 Jun; 6():20. PubMed ID: 16784533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.